ROMAZA: Phase I trial of combination therapy with romidepsin and azacitidine in patients with newly diagnosed, relapsed or refractory Acute Myeloid Leukaemia ineligible for conventional chemotherapy

Trial Profile

ROMAZA: Phase I trial of combination therapy with romidepsin and azacitidine in patients with newly diagnosed, relapsed or refractory Acute Myeloid Leukaemia ineligible for conventional chemotherapy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2017

At a glance

  • Drugs Romidepsin (Primary) ; Azacitidine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Acronyms ROMAZA
  • Most Recent Events

    • 14 Jul 2016 Planned End Date changed from 31 Mar 2016 to 30 Aug 2017.
    • 04 Dec 2015 Accrual to date is 56% according to United Kingdom Clinical Research Network record.
    • 01 Dec 2015 Planned End Date changed from 31 Dec 2015 to 31 Mar 2016, according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top